Abbott Laboratories (ABT) EVP logs 4,997-share tax-withholding disposition on Form 4

Rhea-AI Filing Summary

Abbott Laboratories executive Christopher J. Scoggins reported a tax-related share disposition. On February 27, 2026, he had 4,997 common shares withheld at $116.26 per share in a tax-withholding disposition, classified under code F as payment of tax liability by delivering securities.

After this non-open-market transaction, Scoggins’ directly owned holdings in Abbott Laboratories common shares were reported as 77,126 shares.

Insights

Insider transactions analyst

Routine tax-withholding share disposition with holdings remaining sizable.

The transaction involves an Abbott Laboratories executive using shares to cover tax obligations. Code F indicates a tax-withholding disposition rather than an open-market sale, so it does not signal discretionary selling activity.

Scoggins had 4,997 common shares withheld at $116.26 per share and still directly holds 77,126 shares afterward. This appears to be a routine administrative event linked to equity compensation, with limited implications for broader shareholder sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scoggins Christopher J

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/27/2026		F		4,997	D	$116.26	77,126	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Christopher J. Scoggins by Jessica H. Paik, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abbott Laboratories (ABT) report for Christopher J. Scoggins?

Abbott Laboratories reported that executive Christopher J. Scoggins had shares withheld to cover taxes, not an open-market sale. The Form 4 shows a tax-withholding disposition of 4,997 common shares at $116.26 per share under transaction code F.

How many Abbott Laboratories (ABT) shares were involved in Scoggins’ Form 4 transaction?

The Form 4 shows 4,997 Abbott Laboratories common shares were used in a tax-withholding disposition. These shares were valued at $116.26 each and were applied to satisfy tax liabilities associated with equity compensation, rather than being sold on the open market.

What does transaction code F mean in the Abbott Laboratories (ABT) Form 4 filing?

Transaction code F in the Abbott Laboratories Form 4 indicates payment of an exercise price or tax liability by delivering securities. For Christopher J. Scoggins, it reflects a tax-withholding disposition where 4,997 shares were withheld to cover taxes, not a discretionary stock sale.

How many Abbott Laboratories (ABT) shares does Christopher J. Scoggins hold after this Form 4 event?

After the tax-withholding disposition, Christopher J. Scoggins is reported to directly own 77,126 Abbott Laboratories common shares. This figure reflects his holdings following the 4,997-share transaction used to satisfy tax obligations tied to his equity compensation.

Was the Abbott Laboratories (ABT) insider transaction an open-market sale?

No, the transaction was not an open-market sale. The Form 4 describes a tax-withholding disposition under code F, where 4,997 Abbott Laboratories shares were delivered to cover tax liability, a common administrative step with equity awards rather than a discretionary sale.

What role does Christopher J. Scoggins hold at Abbott Laboratories (ABT) in this Form 4?

Christopher J. Scoggins is listed as an Executive Vice President of Abbott Laboratories in the Form 4. His reported transaction involves using 4,997 common shares for tax-withholding purposes, after which he directly holds 77,126 Abbott Laboratories shares.